Intradialytic parenteral nutrition (IDPN) is a form of supplemental nutrition used to treat patients with malnutrition who receive hemodialysis. Once the diagnosis of malnutrition is made in such patients, encouragement of oral intake is the first-line treatment. If this fails, then enteral or parenteral nutrition may be needed. This review examines the literature on the use of IDPN and summarizes the current recommendations. There is considerable controversy over indications and benefits of IDPN, and well-controlled, longterm studies are needed to help tease out these issues. In the interim, clinical judgment should be used when considering IDPN for individual patients. (Nutr Clin Pract. 2018;33:767-771) 
Background
The presence of protein energy malnutrition (PEM) can be quite common [1] [2] [3] among the hundreds of thousands of patients in the United States who receive hemodialysis, and it independently predicts higher hospitalization rates, lower quality of life, and death. 4 Causes of PEM in hemodialysis patients include reduced food intake from uremia, concurrent illnesses, alterations in the balance between hunger and satiety hormones, dietary restrictions, financial limitations, depression/anxiety, and nutrient and energy losses that occur during the hemodialysis session. [3] [4] [5] Prevention of PEM requires a multidisciplinary effort involving the entire healthcare team. Essential steps to improving nutrition status include liberalizing any dietary restrictions, encouraging food intake, providing oral nutrition supplements, and offering nutrition education. However, these interventions are not always effective in helping the patient achieve his or her nutrition goals. In such cases, intradialytic parenteral nutrition (IDPN), which involves an intravenous (IV) infusion of essential nutrients during hemodialysis treatments, may be helpful as a component of nutrition support.
This discussion will focus on the use of IDPN for patients who are receiving in-center maintenance hemodialysis, who comprise the great majority of dialysis patients in the United States, and will review technical aspects and administration, the appropriate selection of patients, risks and benefits, and evidence supporting its use. The use of IDPN in patients receiving home and peritoneal dialysis will not be covered in this report.
Technical Aspects
There are 2 main types of IDPN. In compounded admixture-based IDPN, all-in-one IDPN bags are mixed by a pharmacy based on individual patient needs. In commercial admixture-based IDPN, premixed bags are provided for generic use. Of the 2, commercial premixed bags are far more popular because the process of compounding single bags based on specific patient needs is time consuming and adds cost. 5 IDPN is administrated via IV infusion with an infusion pump during hemodialysis. Typically the most concentrated IDPN formula is used to reduce the risk for volume overload and fit the treatment within the usual time constraints of a standard hemodialysis session.
A typical IDPN infusion provides 800-1200 kcal in the form of glucose, lipids, and amino acids (usually 30-60 g of the latter). 6 However, some amino acids can be lost in the dialysate depending on the hemodialysis filter used and if they have been reused. 7 Electrolyte-free admixtures (ie, without sodium, potassium, and phosphorus) are also available. 5 When taking into account amino acids and energy that can be lost with each hemodialysis session (ie, 200-480 kcal of energy and 10-12 g of amino acids), 8 not >3000 kcal of energy and 150 g of amino acids will be provided by IDPN with thrice weekly dialysis. Thus, in a 70-kg patient, approximately 6 kcal/kg/d (target being 30-35 kcal/kg/d) of energy 9, 10 and 0.30 g/kg/d (target being 1.2 g/kg/d) of amino acids 9, 10 are provided by IDPN, highlighting the fact that IDPN should be used only as supplemental nutrition in patients with a spontaneous oral nutrition intake of at least 25 kcal/kg/d of energy and 0.9 g/kg/d of amino acids. 5, 9, 11, 12 Evidence Supporting the Use of IDPN Several retrospective and prospective randomized studies have examined the effects of IDPN on clinical end points. Benefits noted included improvements in anthropometric parameters and serum albumin and serum prealbumin albumin levels. [12] [13] [14] [15] One human study that infused stable isotopes to assess muscle turnover during IDPN identified increases in regional and total body protein synthesis. 16 However, in the largest randomized study of IDPN (n = 186), the addition of IDPN to oral nutrition supplementation over 1 year did not improve 2-year mortality rates, hospitalization rates, or general well-being as compared with oral supplements alone. 17 In addition, all of the randomized studies have been open label in design, which increases the opportunity for bias. Moreover, even though most studies used serum albumin level as an inclusion criterion or surrogate outcome representing nutrition improvement, serum albumin level is primarily an indicator of inflammation or illness, thus making interpretation of these studies more challenging. 18 Clearly, longer-term prospective clinical trials with appropriate control groups are needed to identify which type of patient is most likely to benefit from IDPN.
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Selection of Patients for IDPN
The process of selecting patients for IDPN first requires identifying patients who are malnourished. Table 1 includes a list of parameters from the National Kidney Foundation Disease Outcome Quality Initiative (NKF KDOQI) that can be used to identify malnutrition.
11 As Table 1 notes, each of the parameters have limitations, sometimes serious ones, when applied to the hemodialysis population. Therefore, identifying PEM in hemodialysis patients requires a large dose of clinical judgment based on a careful history and physical examination.
Once PEM is identified, IDPN should not be the initial treatment choice. Rather, encouraging increased oral nutrition or supplements like protein drinks or bars through dietary counseling and education is an important first step. Every effort should also be made to ease dietary restrictions and financial constraints that may work to limit food intake. Pharmacological agents such as megestrol and ghrelin may stimulate appetite, and increase serum albumin level and weight; however, these drugs have not been studied systematically, and large-scale prospective studies are needed in patients who are receiving hemodialysis. 19, 20 Moreover, the physician should also search for identifiable causes for PEM. A complete gastrointestinal workup is needed to make sure there are no physical or structural impediments (eg, poor dentation, dysphagia, gastroparesis) to oral intake. Other causes of anorexia such as depression, dementia, or inadequate dialysis should also be excluded.
If despite the efforts described earlier the patient is unable to meet the nutrition intake goals, then the option of IDPN should be discussed. 9 Notably, in patients who are not meeting daily nutrition goals even with oral nutrition supplements and IDPN, placement of a feeding tube for enteral nutrition (EN) or daily parenteral nutrition (PN) may be the appropriate next step. Another subgroup of hemodialysis patients in whom EN or PN may be beneficial are critically ill individuals. These persons should be treated as intensive care patients. 9 Several nephrology and nutrition societies have commented on the management of PEM, including the use of intensive nutrition counseling, dietary oral supplements, and IDPN as shown in Table 2 and Figure 1 . NKF KDOQI guidelines recommend using IDPN in malnourished patients who are receiving dialysis who are not able to increase oral ingestion with dietary counseling, do not tolerate oral supplementation or enteral tube feeding, and have a sufficient spontaneous intake that combined with the nutrients provided by IDPN can reach the nutrition targets.
11 European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines suggest using IDPN in malnourished dialysis patients who had unsuccessful responses to nutrition counseling and oral nutrition supplements. 9 Interestingly, NKF KDOQI recommends IDPN only after EN fails, whereas ESPEN recommends IDPN as first-line therapy when placement of a feeding tube is deemed to be higher risk than IDPN. In contrast, the American Society of Parenteral and Enteral Nutrition does not recommend IDPN because of lack of adequate supporting data. 10 The differences in recommendations between societies is likely due to a lack of high-grade clinical evidence, thus making any judgment about the benefits and risks primarily opinion based. These conflicting recommendations highlight the need for clinical judgment in determining which patients may benefit from IDPN.
When should IDPN be discontinued once initiated? Stopping is reasonable if there is sustained improvement in nutrition parameters, if adverse effects of IDPN are observed (see the following section), or if there is spontaneous improvement of energy/protein intake, thus making IDPN unnecessary. In contrast, lack of improvement after 3-6 months of IDPN should also lead to discontinuation of IDPN. 5 Ultimately the decision to discontinue IDPN, like the decision to initiate it, is based primarily on clinical judgment.
Risks and Advantages of IDPN
There are several benefits and drawbacks of IDPN, all of which are listed in Table 3 . Of particular interest in the known drawbacks are associated metabolic and electrolyte derangements. For example, IDPN is contraindicated if triglyceride levels are >300 mg/dL because lipids present in the IDPN could exacerbate hypertriglyceridemia. Hyperglycemia has also been identified as a possible complication of IDPN. Because of the risk for electrolyte disturbances, stringent monitoring of the electrolytes, especially during the first weeks of IDPN support, is highly recommended. 9 Depending on the compounding of the nutrient solution blood glucose, triglycerides and liver function tests need to be monitored on a routine basis. 21 Overall, IDPN has been demonstrated in hemodialysis patients to be safe with a low complication rate. In the largest randomized study of IDPN ever performed, the most common adverse effects identified were digestive symptoms, hypotension, and muscle cramps that occurred during treatment, although they occurred at a similar rate to the control group (which was consuming oral supplementation). 17 One potential nonmedical complication of IDPN involves its financial impact because cost varies based on insurance coverage. Previously, Medicare Part B required proof of gastrointestinal impairment before coverage. However, because Medicare Part D has covered IDPN under "drug therapies" since 2006, it is now easier to obtain coverage once medical necessity is demonstrated.
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Conclusion
Patients requiring hemodialysis are at risk for PEM, which is linked to a greater likelihood of adverse clinical outcomes. 4 IDPN is a relatively safe and efficacious option for delivering nutrients to hemodialysis patients with reduced spontaneous oral intake. However, it is not designed to be the only or even the major source of nutrition sustenance. It is also not indicated for severely malnourished or critically ill patients who are receiving hemodialysis. No studies have demonstrated that IDPN improves major clinical outcomes, although few randomized trials in this field exist. 23 Therefore, additional studies are needed to establish the benefits of IDPN. In the meantime, clinical judgment and acumen remain key to diagnosing PEM and determining the need for IDPN.
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